Theradaptive
- Company typePrivate
- Founded2016
- HeadquartersFrederick, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Theradaptive does
Theradaptive is a clinical-stage biologics company developing targeted regenerative therapeutics founded in 2016 and headquartered in Frederick, Maryland. The company is built around its proprietary AMP2 protein-engineering platform, a computational and in vitro screening system that converts recombinant proteins such as bone morphogenetic protein-2 (BMP-2) into material-binding variants capable of coating implants, devices, and injectable carriers in a single step. Each variant is novel composition of matter, generating an expanding intellectual property estate. The lead product, OsteoAdapt SP, is an AMP2-coated spinal fusion implant currently in pivotal Phase 3 (OASIS trial) following FDA approval to advance in April 2026, with three FDA Breakthrough Device Designations in hand. A second pipeline product, OsteoAdapt DE, is in Phase I/II (RESTORE trial) for dental alveolar ridge augmentation, and THX-14, a combination product combining AMP2 with ORTHOREBIRTH's ReBOSSIS bone void filler, is licensed for Asia.
Theradaptive operates a pre-revenue, partnership-driven business model. Future U.S. commercialization of OsteoAdapt is structured through an exclusive distribution agreement with Alphatec Holdings (ATEC), granting ATEC U.S. commercial rights in exchange for upfront payments, milestone payments, and a perpetual royalty. Theradaptive separately holds an exclusive Asia license with ORTHOREBIRTH for THX-14 and a co-development partnership with 3D Systems for protein-based 3D printing applications. Non-dilutive capital has come from the U.S. Department of Defense (cumulative prior funding exceeding $11M, a $4M contract in March 2023, and a Clinical Trial Award of up to $7.4M in September 2023), the Maryland Stem Cell Research Fund, and Maryland state Build Our Future grants. Equity funding totals approximately $32.2M to date across a $6.2M seed (January 2021) and a $26M Series A (June 2023), with a Series B initiated in January 2026.
The company targets multiple clinical segments: spinal fusion patients (the primary commercial focus), military service members and veterans with musculoskeletal injuries (supported by DoD funding and the founder's origin story), dental and oral surgery patients, and future indications in targeted oncology chemotherapeutics and vascular/soft tissue repair. Headcount is 11-50 employees, with operational scale-up reflected in a Frederick County manufacturing expansion (ribbon-cutting September 2024) and inclusion in Frederick County's Top 50 Manufacturers list in 2025. The company remains privately held with no parent entity.
Theradaptive firmographics
Firmographics- Name
- Theradaptive
- Legal name
- Theradaptive, Inc.
- Website
- https://theradaptive.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Theradaptive industry classification
Industry- Product category
- Regenerative Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
- akta.pro secondary industry
- Periodontal Regeneration (GTR/EMD/Biologics) (HLABACAI)
Keywords
Where Theradaptive is headquartered
LocationHeadquarters
- HQ city
- Frederick
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Theradaptive business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Strategic Partnership / Distribution Royalties: Pre-commercial milestone and perpetual royalty payments under exclusive U.S. distribution deal with Alphatec Holdings (ATEC) for OsteoAdapt bone graft. Includes upfront payments and milestone payments tied to regulatory and commercial progress, with a perpetual royalty on future sales.
- International Licensing (Asia): Exclusive license to ORTHOREBIRTH for development and commercialization of THX-14 in Asia, with Theradaptive receiving milestone payments and royalties on any future product sales in the licensed territory.
- Government / Defense Grants and Contracts: Non-dilutive funding from U.S. Department of Defense (Clinical Trial Award up to $7.4M in 2023; $4M contract in 2023) and Maryland state programs (MSCRF grants, Build Our Future Grant Program ~$464K in 2026). Used to fund clinical trials, manufacturing scale-up, and product development.
- Venture Capital Investment (Pre-revenue Equity): Pre-revenue clinical-stage company funded through successive venture rounds including $6.2M seed round (Jan 2021) led by AMP Squared Capital Partners with Maryland Venture Fund and OrthoRebirth; $26M Series A (June 2023); and Series B round initiated in January 2026 to fund clinical studies and platform scaling.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Not publicly disclosed — investigational products only |
Go-to-market motion4 records
Distribution channels4 records
Marketing channels6 records
Theradaptive product offering
Product offeringCore offering
Theradaptive is a clinical-stage biologics company developing protein therapeutics through its proprietary AMP2 protein-engineering platform, which computationally converts recombinant proteins into material-binding variants that coat implants, devices, and injectable carriers in a one-step process for targeted, long-term local delivery. The company builds investigational regenerative therapeutics on this platform, with OsteoAdapt SP (a next-generation engineered BMP-2 spinal fusion implant) as its lead product in pivotal Phase 3 OASIS clinical trials, OsteoAdapt DE for dental alveolar ridge augmentation in Phase I/II development, and THX-14 (a partnered combination product for bone trauma).
Product overview
Theradaptive offers a single underlying platform-plus-products architecture centered on its proprietary AMP2 protein-engineering technology. The AMP2 platform converts recombinant proteins (notably a next-generation engineered variant of BMP-2) into material-binding variants that coat implants, devices, and injectable carriers in a one-step process, enabling precise targeted delivery with reduced off-target effects. On top of this core platform, Theradaptive builds a portfolio of clinical-stage regenerative therapeutics, with OsteoAdapt SP as the lead product advancing through pivotal Phase 3 (OASIS) trials for spinal fusion, OsteoAdapt DE in Phase I/II (RESTORE) development for dental alveolar ridge augmentation, and THX-14 (a combination product with ORTHOREBIRTH's ReBOSSIS bone void filler) for bone trauma and congenital skeletal defects. Theradaptive has received three FDA Breakthrough Device Designations for OsteoAdapt SP and is pursuing PMA approval.
Differentiator
Problem solved
Functional benefit
Brands
- OsteoAdapt SP: Investigational regenerative spinal fusion implant containing AMP2 protein, designed as an alternative to autologous and allograft bone grafts; currently in pivotal Phase 3 OASIS trial for degenerative disc disease.
- OsteoAdapt DE
- AMP2
Products and services
- AMP2 Platform
Quantifiable outcome
- FDA approval to advance OASIS Trial from Phase 2 to pivotal Phase 3 for OsteoAdapt SP in spinal fusion
- +4 more outcomes
Companies that use Theradaptive
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles4 records
Theradaptive technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Theradaptive partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered flagship, minor, major and core.
- Alphatec Holdings (ATEC)flagshipStrategic partnership granting Alphatec Holdings exclusive U.S. commercial rights to market and distribute Theradaptive's OsteoAdapt® osteoinductive bone graft for spinal fusion. Deal structure includes upfront payments, milestone payments, and a perpetual royalty arrangement. Concurrently, Theradaptive initiated a Series B financing round to support clinical studies and AMP2 platform scaling. ATEC also collaborating on a next-generation BMP with faster bone formation properties.
- Latham & WatkinsminorLatham & Watkins advised Theradaptive on the strategic partnership with Alphatec Holdings (ATEC). Legal counsel role on the transaction.
- 3D SystemsmajorCommercial partnership (announced August 2023) to advance orthopedic and soft tissue repair using Theradaptive's breakthrough regenerative therapeutics combined with 3D Systems' protein-based 3D printing materials. Referenced as a key 2023 innovation in Maximize Market Research's 3D Printing Materials outlook.
- ORTHOREBIRTH Co., Ltd.majorExclusive license agreement for THX-14 (AMP2-coated ReBOSSIS combination product for bone trauma and congenital skeletal defects with option to extend into spinal fusion). ORTHOREBIRTH holds exclusive Asia development and commercialization rights; Theradaptive retains U.S. and Europe rights and receives milestone payments and royalties. Jointly responsible for global clinical studies and commercial launch coordination.
- Cleveland CliniccoreResearch collaborator — conducted pivotal preclinical studies of AMP2 and THX-14 (e.g., 5cm caprine tibial defect model, BM-MSC studies). Dr. George Muschler, Professor of Orthopedic Surgery and Biomedical Engineering at Cleveland Clinic, is a member of Theradaptive's Physician-Scientist Advisory Board.
- Mayo ClinicmajorClinical trial site partner for the OASIS pivotal trial of OsteoAdapt SP (with surgeons Arjun Sebastian, MD; Benjamin Elder, MD; Melvin Helgeson, MD). Mayo Clinic is also referenced as a site of preclinical study collaboration demonstrating AMP2 superiority over standard of care.
Scale indicators13 records
Recent moves7 records
Expansion highlights6 records
Theradaptive competitors and assessment
Company assessmentMarket position
Strengths1 record
Weaknesses5 records
Competitive moat5 records
Customer concentration
Theradaptive social profiles
Digital presenceTheradaptive financial estimates
Financial estimateRevenue estimate
Valuation estimate
Theradaptive leadership team
Management profileNumber of profiles
Profiles10 records
Theradaptive funding detail
Funding detailFunding overview
Funding rounds9 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Theradaptive M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Theradaptive
What does Theradaptive do?
Theradaptive is a clinical-stage biologics company developing protein therapeutics through its proprietary AMP2 protein-engineering platform, which computationally converts recombinant proteins into material-binding variants that coat implants, devices, and injectable carriers in a one-step process for targeted, long-term local delivery. The company builds investigational regenerative therapeutics on this platform, with OsteoAdapt SP (a next-generation engineered BMP-2 spinal fusion implant) as its lead product in pivotal Phase 3 OASIS clinical trials, OsteoAdapt DE for dental alveolar ridge augmentation in Phase I/II development, and THX-14 (a partnered combination product for bone trauma).
Is Theradaptive a public or private company?
Theradaptive is a private company. It is classified as venture growth investor backed and is currently operating.
When was Theradaptive founded?
Theradaptive was founded in 2016. It employs 11 to 50 people.
Where is Theradaptive based?
Theradaptive is headquartered in Frederick, United States, in the North America region.
How does Theradaptive make money?
Four revenue lines are on record. Strategic Partnership / Distribution Royalties are the primary driver. The others are international Licensing (Asia), government / Defense Grants and Contracts and venture Capital Investment (Pre-revenue Equity).
Does Theradaptive have an API?
No public API is recorded for Theradaptive.
What industry is Theradaptive in?
Theradaptive's product category is Regenerative Therapeutics. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLABACAI, Periodontal Regeneration (GTR/EMD/Biologics). Its NAICS code is 325414 and its SIC code is 3841.